- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06110208
Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML
October 26, 2023 updated by: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Clinical Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T Injection in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
This study is a single-center clinical study.
The main purpose is an IIT clinical trial to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual CAR-T injection in r/r AML subjects .
The included population were patients with relapsed and refractory acute myeloid leukemia (r/r AML) .
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Single-center clinical study.
The main purpose is an IIT clinical trial to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual CAR-T injection in r/r AML subjects .
The included population was patients with relapsed and refractory acute myeloid leukemia (r/r AML) .
Study Type
Interventional
Enrollment (Estimated)
18
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sanbin Wang
- Phone Number: (86)13187424131
- Email: Sanbin1011@163.com
Study Locations
-
-
Yunnan
-
Kunming, Yunnan, China, 650000
- Recruiting
- 920th Hospital of Joint LogisticsSupport Force of People's Liberation
-
Contact:
- Sanbin Wang, Professor
- Phone Number: +86 13187424131
- Email: Sanbin1011@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 18-70 years old (including the critical value) when signing the informed consent form;
- Diagnosed with acute myeloid leukemia (excluding APL) according to the World Health Organization 2016 criteria and relapsed and refractory AML according to the ELN2022 criteria;
- Positive expression of CLL1 and/or CD38 in malignant cells must be detected by immunohistochemistry or flow cytometry (≥20 % );
- If there are AEs caused by previous chemotherapy, it must be restored to CTCAE V5.0 grade 1;
- Estimated survival time ≥3 months;
- ECOG score 0 or 1 during screening period;
- Hemoglobin ≥80g/L (have not received red blood cell transfusion within 7 days before screening, use of recombinant human erythropoietin is allowed);
Adequate organ functional reserve:
- Alanine aminotransferase/aspartate aminotransferase ≤2.5× ULN (upper limit of normal value);
- Serum total bilirubin ≤2× ULN, except for subjects with congenital bilirubinemia (for subjects with Gilbert syndrome, direct bilirubin needs to be ≤1.5× ULN);
- Serum creatinine clearance >45mL/min (calculated according to the Cockcroft-Gault formula);
- Left ventricular ejection fraction ≥35%;
- Basic oxygen saturation in indoor air environment is ≥ 92 %
- Ability to discontinue corticosteroids (dexamethasone ≥3 mg/day or other equivalent doses of steroids) starting on day -7 and continuing until 30 days after CAR-T cell infusion;
- Women of childbearing age must have a negative pregnancy test for human chorionic gonadotropin (HCG) (immunofluorescence method) during the screening period and baseline period. Male subjects will need to agree not to donate sperm for at least one year after reinfusion. Males and sexual partners of childbearing potential agree to use highly effective contraceptive measures for at least 1 year after infusion;
- Agree to perform follow-ups in accordance with the requirements of the protocol and informed consent form;
- With the consent of the subject and the informed consent form voluntarily signed by the subject or his legal representative.
Exclusion Criteria:
- Diagnosis of acute promyelocytic leukemia;
- clinical trial investigational drugs or cell therapies within 2 weeks or 5 half-lives ;
- Acute myeloid leukemia of unknown lineage ;
- Those who have active graft-versus-host disease (GVHD) at the time of enrollment or develop active acute or chronic GVHD within 4 weeks after enrollment or require immunosuppressive drugs to treat GVHD;
- There is an active infection;
- Suffering from other malignant tumors (except non-melanoma skin cancer and in situ cervical cancer, bladder cancer, and breast cancer with a disease-free survival period of more than 5 years);
- The subject has had a stroke or epilepsy within 6 months before signing the informed consent form;
The subjects' cardiac function showed the following conditions:
- New York Heart Association (NYHA) class III or IV heart failure;
- Myocardial infarction or coronary artery bypass grafting (CABG) occurred within 6 months before signing the informed consent form;
- A history of clinically significant ventricular arrhythmia or syncope of unknown origin (not caused by vasovagal or dehydration);
- Have a history of severe non-ischemic cardiomyopathy;
- Cardiac dysfunction (left ventricular <35%) assessed by echocardiography or multiple gated acquisition scans, or other heart disease with clinical symptoms within 6 months before enrollment;
- Active or previous central nervous system involvement, or clinically significant clinical manifestations of central nervous system involvement in subjects with acute myeloid leukemia ;
A positive virological test result for any of the following:
- Human immunodeficiency virus antibodies (HIV antibodies);
- Hepatitis C virus antibody (HCV antibody), those who are positive need to be tested for HCV-RNA, and those whose values are lower than the lower limit of the detection value can be enrolled;
- HBsAg positive; or HBcAb positive; if HBcAb is positive, further testing of HBV DNA copy number is required . Those who are lower than the lower limit of the detection value can be enrolled;
- Treponema pallidum antibodies (TPPA antibodies);
- presence of pulmonary fibrosis;
- Severe allergic history or allergic constitution;
- The subject has undergone open injury or major surgery (referring to level III surgery and level IV surgery) within 2 weeks before signing the informed consent form, or plans to have surgery during the trial or within 2 weeks after reinfusion (excluding local anesthesia surgery) ;
- for cyclophosphamide combined with fludarabine ;
- Cannulae or drains other than central venous catheters;
- Pregnant women, lactating women, or men who plan to give birth within 1 year of receiving treatment;
- Any other circumstances that the researcher deems inappropriate for inclusion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AML subjects
This study is a single-center clinical study.
The main purpose is an IIT clinical trial to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual CAR-T injection in r/r AML subjects .
The included population was patients with relapsed and refractory acute myeloid leukemia (r/r AML) .
|
CLL1 and CD38 dual-target CAR-T injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose limited toxicity (DLT);
Time Frame: 28 days after CAR-T infusion
|
Dose limited toxicity (DLT);
|
28 days after CAR-T infusion
|
Adverse events (AE)
Time Frame: 48 weeks after CAR-T infusion
|
• Adverse events (AE): CTCAE version 5.0 standards will be used for rating
|
48 weeks after CAR-T infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
• Overall response rate (ORR);
Time Frame: 1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
defined as the proportion of subjects who achieved CR, CR with partial hematologic recovery(CRh), CR with incomplete hematologic recovery (CRi), morphologic leukemia-free status (MLFS), or partial remission (PR).
|
1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
• Overall complete response rate (CRR);
Time Frame: 1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
defined as the proportion of subjects who achieved morphological complete response (CR),CR with partial hematologic recovery(CRh) and complete response with incomplete hematological recovery ( CRi ).
|
1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
• Partial response rate (PRR);
Time Frame: 1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
defined as the proportion of subjects achieving partial response (PR).
|
1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
• The proportion of patients who achieved complete remission (CR) who tested negative for MRD (MRD-rate);
Time Frame: 1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
only used to evaluate subjects who achieve CR,CRh and CRi .
In this study, the proportion of MRD-negative subjects was detected by flow cytometry.
Sensitivity is defined as: collecting 100,000 nucleated cells in a bone marrow sample, of which the number of leukemia cells is less than 10 (i.e., MRD level <10 -4 ).
Response with MRD detection at low-level (CRMRD-LL) is included in this category of CR, CRh or CRi with MRD-negative.
CRMRD-LL is currently only defined for NPM1-mutant and CBF-AML
|
1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
• Median bone marrow blast percentage decline;
Time Frame: 1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
Median bone marrow blast percentage decline;
|
1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
• Relapse-free survival (RFS);
Time Frame: 1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
defined only for patients achieving CR, CRh, or CRi; measured from the date of achievement of remission until the date of hematologic relapse or death from any cause; patients not known to have relapsed or died at last follow-up are censored on the date they were last known to be alive.
|
1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
• Event-free survival (EFS);
Time Frame: 1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
used to evaluate all subjects .
It is calculated from the start of cell infusion until treatment failure, relapse or death (various reasons).
Subjects without the above events will be counted until the last follow-up examination date.
For patients who did not achieve CR/CRh/ CRi , EFS was calculated from the start of cell infusion until disease progression or death.
The first event shall prevail.
|
1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
• Overall survival (OS);
Time Frame: 1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
used to evaluate all subjects.
The time from cell infusion to death from any cause was calculated.
|
1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
• Duration of response (DOR);
Time Frame: 1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
refers to the time from the first evaluation of CR, CRh, CRi , MLFS or PR to the first evaluation of disease recurrence or progression or death from any cause.
|
1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
• Expansion and persistence of CAR-T cells (CAR copy number and CAR - T cell number)
Time Frame: Days 4, 7, 10, 14 ,21,28 and months 2, 3, 6, 9, 12 after Fast Dual CAR-T infusion
|
CAR copy number and CAR - T cell number
|
Days 4, 7, 10, 14 ,21,28 and months 2, 3, 6, 9, 12 after Fast Dual CAR-T infusion
|
• The proportion of subjects with RCL detected in peripheral blood and the insertion site of CAR-T cell lentivirus within 15 years after the infusion of CLL1 and CD38 dual-target CAR-T injection.
Time Frame: within 15 years after the infusion of CLL1 and CD38 dual CAR-T injection
|
• The proportion of subjects with RCL detected in peripheral blood and the insertion site of CAR-T cell lentivirus within 15 years after the infusion of CLL1 and CD38 dual-target CAR-T injection.
|
within 15 years after the infusion of CLL1 and CD38 dual CAR-T injection
|
• CR with partial hematologic recovery rate (CRhR);
Time Frame: 1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
defined as the proportion of subjects who achieved CR with partial hematologic recovery.
|
1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
• CR with incomplete hematologic recovery rate (CRiR);
Time Frame: 1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
defined as the proportion of subjects who achieved CR with incomplete hematologic recovery
|
1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
• Morphologic leukemia-free state rate (MLFSR);
Time Frame: 1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
defined as the proportion of subjects who achieved Morphologic leukemia-free state
|
1month, 2 months, 3months, 6months ,9months,12months after CAR-T infusion
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
• Explore the correlation between serum cytokines, Cytokine Release Syndrome (CRS) and neurotoxicity after infusion of CLL1 and CD38 dual-target CAR-T injection;
Time Frame: Days 4, 7, 10, 14 ,21,28 and months 2, 3, 6, 9, 12 after Fast Dual CAR-T infusion
|
• Explore the correlation between serum cytokines, Cytokine Release Syndrome (CRS) and neurotoxicity after infusion of CLL1 and CD38 dual-target CAR-T injection;
|
Days 4, 7, 10, 14 ,21,28 and months 2, 3, 6, 9, 12 after Fast Dual CAR-T infusion
|
• Explore the correlation between the number of CAR-T cells in the blood/bone marrow/tumor tissue of subjects and CRS and neurotoxicity after infusion of CLL1 and CD38 dual-target CAR-T injection;
Time Frame: Days 4, 7, 10, 14 ,21,28 and months 2, 3, 6, 9, 12 after Fast Dual CAR-T infusion
|
• Explore the correlation between the number of CAR-T cells in the blood/bone marrow/tumor tissue of subjects and CRS and neurotoxicity after infusion of CLL1 and CD38 dual-target CAR-T injection;
|
Days 4, 7, 10, 14 ,21,28 and months 2, 3, 6, 9, 12 after Fast Dual CAR-T infusion
|
• Explore the correlation between CAR copy number and CRS and neurotoxicity in the blood/bone marrow/tumor tissue of subjects after infusion of CLL1 and CD38 dual-target CAR-T injection;
Time Frame: Days 4, 7, 10, 14 ,21,28 and months 2, 3, 6, 9, 12 after Fast Dual CAR-T infusion
|
• Explore the correlation between CAR copy number and CRS and neurotoxicity in the blood/bone marrow/tumor tissue of subjects after infusion of CLL1 and CD38 dual-target CAR-T injection;
|
Days 4, 7, 10, 14 ,21,28 and months 2, 3, 6, 9, 12 after Fast Dual CAR-T infusion
|
• Explore the proportion of subjects who has detectable anti-CLL1 and CD38 dual CAR-T antibodies within 48 weeks after infusion of CLL1 and CD38 dual CAR-T injection;
Time Frame: 48 weeks after CAR-T infusion
|
• Explore the proportion of subjects who has detectable anti-CLL1 and CD38 dual CAR-T antibodies within 48 weeks after infusion of CLL1 and CD38 dual CAR-T injection;
|
48 weeks after CAR-T infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Sanbin Wang, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 10, 2023
Primary Completion (Estimated)
August 1, 2026
Study Completion (Estimated)
October 1, 2026
Study Registration Dates
First Submitted
October 26, 2023
First Submitted That Met QC Criteria
October 26, 2023
First Posted (Actual)
October 31, 2023
Study Record Updates
Last Update Posted (Actual)
October 31, 2023
Last Update Submitted That Met QC Criteria
October 26, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GC12-132
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on CLL1 and CD38 dual-target CAR-T injection
-
Chinese PLA General HospitalUnknown
-
Shenzhen University General HospitalUnknownRefractory B Acute Lymphoblastic Leukemia | Relapse | B ALL | Dual-target CAR-T CellsChina
-
Xijing HospitalGracell Biotechnology Ltd.Unknown
-
YuLiUnknownLymphoma, B-Cell | Refractory Lymphoma | Relapse/Recurrence | Dual-target CAR-T CellsChina
-
Beijing Boren HospitalRecruitingAcute Myeloid LeukemiaChina
-
Zhejiang UniversityNot yet recruiting
-
Hebei Yanda Ludaopei HospitalGracell Biotechnology Ltd.UnknownMultiple MyelomaChina
-
920th Hospital of Joint Logistics Support Force...Withdrawn
-
He HuangYake Biotechnology Ltd.RecruitingRelapsed and Refractory | Lymphoid Hematological MalignanciesChina
-
Beijing Tiantan HospitalTasly Pharmaceutical Group Co., Ltd; Beijing Neurosurgical InstituteRecruiting